Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MC4R | P32245 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | MC3R | P41968 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | GABRP | O00591 | 2/20 | 0.36 |
| ▸ | GABRD | O14764 | 2/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.36 |
| ▸ | GABRE | P78334 | 2/20 | 0.36 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31156798 | 0.90 | HSP90AA1 (0.39) | SIRT6ADORA3TSHRMC4RADRA1A | |
| SCHEMBL30482944 | 0.87 | DPP4 (0.40) | SIRT6ADORA3TSHRMC4RADRA1A | |
| SCHEMBL31696048 | 0.85 | SIRT6 (0.40) | SIRT6ADORA3TSHRMC4RADRA1A | |
| SCHEMBL30301164 | 0.85 | DGAT1 (0.40) | SIRT6ADORA3TSHRMC4RADRA1A | |
| SCHEMBL31156772 | 0.81 | SIRT6 (0.37) | SIRT6ADORA3TSHRMC4RADRA1A | |
| SCHEMBL30644661 | 0.81 | SIRT6 (0.37) | SIRT6ADORA3TSHRMC4RADRA1A | |
| SCHEMBL30482956 | 0.81 | SIRT6 (0.40) | SIRT6ADORA3TSHRMC4RADRA1A | |
| SCHEMBL30482992 | 0.79 | DGAT1 (0.41) | DGAT1SOAT1 | |
| SCHEMBL30300824 | 0.79 | ADORA3 (0.35) | SIRT6ADORA3TSHRMC4RADRA1A | |
| SCHEMBL4864337 | 0.78 | GABRP (0.38) | SIRT6ADORA3TSHRMC4RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312335-A1 | FLT COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR | BIOMEA FUSION, INC. | 2025-10-09 | — | — | US | disclosed |
| US-20250136558-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | BIOMEA FUSION, INC. | 2025-05-01 | — | — | US | disclosed |
| CN-118829631-A | Pyrazine compounds as FLT3 inhibitors | 拜欧米富士恩公司 | 2024-10-22 | — | — | CN | disclosed |
| US-20240262795-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | BIOMEA FUSION, INC. | 2024-08-08 | — | — | US | disclosed |
| EP-4370506-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | Biomea Fusion, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-11945785-B2 | Pyrazine compounds as inhibitors of FLT3 | BIOMEA FUSION, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| US-20230339867-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | BIOMEA FUSION, INC. | 2023-10-26 | — | — | US | disclosed |
| WO-2023129667-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | BIOMEA FUSION, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262795-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | FLT3, MCL1, CSF3R | SIRT6 686/4885ADORA3 3539/4885TSHR 2437/4885 |
| US-20250136558-A1 | PYRAZINE COMPOUNDS AS IRREVERSIBLE INHIBITORS OF FLT3 | FLT3, MCL1, JAK2 | SIRT6 820/4885ADORA3 2570/4885TSHR 1908/4885 |
| US-11945785-B2 | Pyrazine compounds as inhibitors of FLT3 | FLT3, MCL1, JAK2 | SIRT6 847/4885ADORA3 3402/4885TSHR 2204/4885 |
| US-20230339867-A1 | PYRAZINE COMPOUNDS AS INHIBITORS OF FLT3 | FLT3, MCL1, CSF3R | SIRT6 686/4885ADORA3 3539/4885TSHR 2437/4885 |
| US-20250312335-A1 | FLT COMBINATION THERAPY FOR CANCER AND COMPOSITIONS THEREFOR | FLT3, MEN1, FEM1B | SIRT6 785/4885ADORA3 2774/4885TSHR 4051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.